louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04274309: Safety Validation of EndoSWIR Device
Official title: Evaluation of the Medical Device ex Vivo ENDOSWIR in Patient Operated for a Tonsillectomy : a Preliminary Cohort Study Proof of Concept (ENDOSWIR-AMYG)
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Optical Guided Surgery
Lead sponsor: University Hospital, Grenoble
Sponsor class: OTHER
Collaborators: name: Institut National de la Santé et de la Recherche Médicale, Institute for Advanced Biosciences
name: Commissariat A L'energie Atomique
name: Lynred
First posted: 2020-02-18
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Men or Women more than 18

Brief summary: Head and neck cancer has an incidence of 600,000 cases per year worldwide (6th among cancers) and cause 380,000 death per year. Surgical resection is guided by the surgeon's inspection and palpation of the tumor. The prognosis of patients depends on the quality of the lesion's resection. The ENDOSWIR dispositive developed by engineers of Atomic Energy Comity of Grenoble allows for reliable and accurate analysis of tumor margins.

The camera provides a spectral analysis of the tissues according to their composition. We want to show that the prognosis of patients is improved by the use of this device. For that we need to prove first that it is not toxic for tissue analysis.

Detailed description: ENDOSWIR dispositive is a InGaAs (Indium Gallium Arsenide) camera working at ambient temperature. The light is a quartz-tungstene-halogeno (QTH) source and the collected beam is filtered to illuminate in different precise wavelength bands in the short wave domain.

We will use it on tonsil tissue just after tonsillectomy and just before the histological analysis.

Eligibility criteria: Inclusion Criteria:

* Tonsillectomy

Exclusion Criteria:

* suspicion of Head-and neck cancer

Primary outcomes:
measure: Tissue integrity
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
city: Grenoble Cedex 9
country: France
facility: Chu Grenoble Alpes
Study officials:
affiliation: University Hospital, Grenoble
name: Christian RIGHINI
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05159609: Closed Loop Auditory Stimulus in Sleep and epilepsY
Official title: Closed Loop Auditory Stimulus in Sleep and epilepsY
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Temporal Lobe Epilepsy
Keywords: Closed loop auditory stimulus
sleep
memory
Lead sponsor: Cardiff and Vale University Health Board
Sponsor class: OTHER_GOV
First posted: 2021-12-16
Enrollment: 17
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: Within subject comparison of stimulus and sham sessions
Primary purpose: BASIC_SCIENCE

Brief summary: This is a single-centre pilot study of a non-invasive auditory stimulation during sleep in participants with temporal lobe epilepsy.

Detailed description: The primary objectives will be to pilot the use of home-based auditory stimulation during sleep in 10-20 participants with temporal lobe epilepsy using wireless devices.

Eligibility criteria: Inclusion Criteria:

1. Participant is willing and able to give informed consent
2. Participant diagnosed with temporal lobe epilepsy
3. Will have had fewer than three generalized tonic clonic seizures per month in the last three months
4. Will be taking 3 or fewer anti-seizure medications.
5. Will have access to a computer or cellphone with an internet connection

Exclusion Criteria:

1. Abnormal hearing that cannot be corrected to normal overnight.
2. Abnormal vision that cannot be corrected to normal during the day.
3. Unwilling to abstain from caffeine, alcohol, daytime naps and extreme physical exercise in the 12 hours prior to the study.
4. Cannot read English
5. Engaged in night work in the previous 2 months
6. Any history of seizures triggered by music or sounds
7. Travelled across more than 2 time zones in the last 2 months
8. Prescribed/taking sleeping tablets other than clobazam
9. Cannabis use \>4 joints/day.

Primary outcomes:
measure: Change in EEG waveform amplitude
timeFrame: 5 seconds after stimulus
measure: Change in Serial Reaction Time Task memory test
timeFrame: Baseline and following day
measure: Change in Paired Associates Learning memory test
timeFrame: Baseline and following day
Secondary outcomes:
Other outcomes:
Locations:
city: Cardiff
country: United Kingdom
facility: Cardiff and Vale UHW, Neurology department, ward C4, video-EEG monitoring unit
Study officials:
affiliation: University Hospital of Wales/Cardiff University
name: Khalid Hamandi, MRCP/Phd
role: PRINCIPAL_INVESTIGATOR
affiliation: University Hospital of Wales/Cardiff University
name: Jennifer Roebber, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00535509: Phase II Trial of Neoadjuvant[FEC100]/Cisplatin-Docetaxel ± Trastuzumab in Women With Over Expressed or Amplified Her2/Neu With Locally Advanced Breast Cancer
Official title: Phase II Trial of Neoadjuvant[FEC100]/Cisplatin-Docetaxel ± Trastuzumab in Women With Over Expressed or Amplified Her2/Neu With Locally Advanced Breast Cancer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Breast Cancer
Lead sponsor: King Faisal Specialist Hospital & Research Center
Sponsor class: OTHER
First posted: 2007-09-26
Enrollment: 285
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Phase II trial of Neoadjuvant \[FEC100\]/Cisplatin-Docetaxel ± Trastuzumab in women with over expressed or amplified Her2/Neu with Locally advanced Breast Cancer


Eligibility criteria: Inclusion Criteria:

* Patients with locally advanced breast cancer

Primary outcomes:
measure: Efficacy
timeFrame: overall
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: KFSH&RC
name: Taher Twegieri, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: KFSH&RC
name: Dahish Ajarim, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT06217809: EmpowHer is a Gender-specific Teen Pregnancy Prevention Curriculum for Middle School-aged Girls.
Official title: EmpowHer, a Gender-specific Teen Pregnancy Prevention Curriculum for Middle School-aged Girls.
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Abstinence, Sex
Lead sponsor: Alternatives For Girls
Sponsor class: OTHER
First posted: 2024-01-23
Enrollment: 552
Sex: FEMALE
Minimum age (years): 10
Maximum age (years): 15
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: Alternatives For Girls (AFG's) EmpowHer curriculum is a program for pre-and early middle school girls (ages 10-15). The curriculum is gender-specific (girls), youth-co-led, and innovative (using online platforms and digitized presentation of material that targets minority/high-risk African American and Latina girls). EmpowHer addresses four adulthood preparation subjects (APS), such as parent-child communication, healthy relationships, adolescent development, and healthy life skills, and is implemented as an after-school program.


Eligibility criteria: Inclusion Criteria:

Females in 6th - 8th grade who are 10 -15 years of age at the start of the study and residing in Detroit or Out Wayne County at the time of enrollment will be eligible to participate in the study.

Exclusion Criteria:

Participants who are currently utilizing other services from Alternatives For Girls (AFG) will not be eligible to participate and will be wait-listed until they are no longer receiving other services from AFG (i.e., after-school programs, summer day camps, mentoring, youth leadership programs, and shelter services). These services are unrelated to the study/sexual health education and do not include EmpowHer or Sassy Science. If siblings were to be enrolled, one would be randomly assigned, and the rest would be allowed to participate in the same group as the study sibling but not counted in the evaluation. This is to prevent possible contamination between conditions.

Primary outcomes:
measure: Recent sexual activity
timeFrame: At 9-month follow up.
measure: Abstinence
timeFrame: At 9-month follow up.
Secondary outcomes:
measure: Healthy relationship knowledge
timeFrame: After 20-hour intervention (at post-test).
Other outcomes:
Locations:
city: Detroit
country: United States
facility: Alternatives For Girls
state: Michigan
Study officials:
References:
Clinical trial NCT01388309: An Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to DMARDs
Official title: DAS Evaluation of RA Activity in Patients Treated With Tocilizumab
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Rheumatoid Arthritis
Lead sponsor: Hoffmann-La Roche
Sponsor class: INDUSTRY
First posted: 2011-07-06
Enrollment: 64
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with rheumatoid arthritis and an inadequate response to DMARDs who are initiated on treatment with RoActemra/Actemra

Brief summary: This observational study will evaluate in clinical practice the change in Disease Activity Score (DAS28) in patients with rheumatoid arthritis and an inadequate response to DMARDs who are initiated on treatment with RoActemra/Actemra (tocilizumab). Data will be collected from eligible patients (on 8 mg/kg or 4 mg/kg intravenously every 4 weeks, with or without methotrexate) for 12 months.


Eligibility criteria: Inclusion Criteria:

* Adult patients, \>/= 18 years of age
* Moderate to severe active rheumatoid arthritis
* Inadequate response or intolerance to previous therapy with one or more traditional DMARDs

Exclusion Criteria:

* Pregnant or lactating women
* Active infection
* Positive for hepatitis B, hepatitis C or HIV infection
* Concomitant anti-TNF drugs
* Contraindications to treatment with RoActemra/Actemra

Primary outcomes:
measure: Disease activity score (DAS28)
timeFrame: 12 months
Secondary outcomes:
measure: DAS 28 (subgroup on monotherapy)
timeFrame: 12 months
measure: DAS 28 (subgroup on 4 mg/kg dose)
timeFrame: 12 months
measure: Safety: Incidence of adverse events
timeFrame: 12 months
Other outcomes:
Locations:
city: Banska Bystrica
country: Slovakia
city: Bratislava
country: Slovakia
city: Kosice
country: Slovakia
city: Piestany
country: Slovakia
Study officials:
affiliation: Hoffmann-La Roche
name: Clinical Trials
role: STUDY_DIRECTOR
References:
Clinical trial NCT01301209: Recto-Anal-Repair in the Treatment of Advanced Haemorrhoidal Disease
Official title: Prospective Observational Study of Recto-Anal-Repair in the Treatment Haemorrhoidal Disease Stage III/IV
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Haemorrhoids
Lead sponsor: Medical University of Vienna
Sponsor class: OTHER
First posted: 2011-02-23
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients with haemorrhoids stage III/IV

Brief summary: Prospective observational study to evaluate the impact of Recto-Anal-Repair (a technique of ultrasound guided haemorrhoidal ligation) in the treatment of stage III/IV haemorrhoidal disease.


Eligibility criteria: Inclusion Criteria:

* Stage III or IV hemorrhoidal disease (Appendix A)
* Patient age 18-80 years old
* Patient fit for general or local anesthesia
* No prior surgical treatment for hemorrhoidal disease
* No prior surgical treatment for anorectal sepsis
* Signed informed consent

Exclusion Criteria:

* Stage I or II hemorrhoidal disease (Appendix A)
* Patient unfit for surgery
* Clotting disorders
* Anal or colorectal malignancy
* Secondary hemorrhoidal disease
* Pregnancy
* Unwilling or unable to sign informed consent

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Vienna
country: Austria
facility: Dept. of Surgery, Medical University Vienna
Study officials:
affiliation: Medical University Vienna
name: Sebastian Roka, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00000309: Serotonin/Dopamine Antagonism of Cocaine Effect: 1 - 1
Official title: Serotonin/Dopamine Antagonism of Cocaine Effect
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Cocaine-Related Disorders
Keywords: cocaine abuse, cocaine addiction
Lead sponsor: Butler Hospital
Sponsor class: OTHER
Collaborators: name: National Institute on Drug Abuse (NIDA)
name: VA Boston Healthcare System
First posted: 1999-09-21
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate use of risperidone with cocaine abusers. Study measures incorporate an appropriate integration of behavioral and neurobiological indices.


Eligibility criteria: Please contact site for information.

Primary outcomes:
measure: Analog mood scales
measure: POMS
measure: EPS sx
Secondary outcomes:
Other outcomes:
Locations:
city: Providence
country: United States
facility: Brown University School of Medicine
state: Rhode Island
Study officials:
affiliation: Brown University
name: Lawrence Price, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04980209: The Feasibility and Application of Intraoperative Ultrasound to Evaluate Femoral Head Shaping
Official title: The Feasibility and Application of Intraoperative Ultrasound to Evaluate Femoral Head Shaping
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Femoroacetabular Impingement
Lead sponsor: Peking University Third Hospital
Sponsor class: OTHER
First posted: 2021-07-28
Enrollment: 78
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: According to the sequential test, the enrolled patients were divided into ultrasound evaluation group and no ultrasound evaluation group. Inclusion Criteria included patients with hip pain; Cam type (alpha Angle \> 50°) impingement and glenoid labrum laceration.

Brief summary: To assess the feasibility of using intraoperative ultrasound to evaluate the femoral head formation; to evaluate the improvement of the forming effect using the intraoperative ultrasound combined with c-arm.

Detailed description: Ultrasound can provide a multi-directional scan of the femoral head and neck junction, and the range of evaluation is larger than that of the intraoperative c-arm. The study was to assess the feasibility of using intraoperative ultrasound to evaluate the femoral head formation; to evaluate the forming of the femoral head and the improvement of the forming effect using the intraoperative ultrasound combined with c-arm.

Eligibility criteria: Inclusion Criteria:

* Patients with hip pain;
* Cam type (alpha Angle \> 50°) impingement and glenoid labrum laceration

Exclusion Criteria:

* Previous hip surgery;
* Patients with subosseous cystic degeneration of synovitis

Primary outcomes:
measure: VAS scale
timeFrame: 1 year after operation
measure: MHHS scale
timeFrame: 1 year after operation
measure: Hip CT
timeFrame: 1 day after operation
measure: Hip X-ray
timeFrame: 1 day after operation
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: Peking Univesity Third Hospital
state: Beijing
Study officials:
affiliation: Peking University Third Hospital
name: Cui Ligang
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05245578: Safety Evaluation of KX01 Ointment 1% in Japanese Healthy Male Subjects
Official title: Skin Irritation and Phototoxicity Study of KX01 Ointment 1% in Japanese Healthy Male Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy Volunteer
Keywords: Skin Irritation
Phototoxicity
Lead sponsor: PharmaEssentia
Sponsor class: INDUSTRY
Collaborators: name: PharmaEssentia Japan K.K.
First posted: 2022-02-18
Enrollment: 20
Sex: MALE
Minimum age (years): 20
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Skin Irritation and Phototoxicity Study of KX01 Ointment 1% in Japanese healthy male subjects

Detailed description: A baseline evaluation of the patch sites will be performed immediately prior to application of the patches to ensure that no conditions, markings, or coloration of the skin will interfere with interpretation of the study results.

A total of 4 application sites (2 cm x 2 cm each) will be marked on each subject's back, placing 2 sites for KX01KX2-391 ointment 1% and 2 sites for Placebo vehicle ointment. One set (KX01 ointment 1% IP and Placebo ointment vehicle patches) will be designated for irradiation and the other set will remain non-irradiated under open conditions. The distance between the patches will be no less than one centimeter.

The numbering of the test sites will remain the same throughout the study. The sites will be marked with an indelible, surgical marker.

Eligibility criteria: Inclusion Criteria:

* Healthy Japanese male adult, whose age 20-65 years old

Exclusion Criteria:

* History of photosensitivity or photoallergy

Primary outcomes:
measure: Degree of skin irritation at application site
timeFrame: 9 days
measure: Phototoxic potential at application site
timeFrame: 9 days
Secondary outcomes:
measure: Number of participants with adverse events as a measure of safety
timeFrame: 9 days
Other outcomes:
Locations:
city: Toshima-ku
country: Japan
facility: Medical Corporation HOUEIKAI, Sekino Clinical Pharmacology Clinic
state: Tokyo
Study officials:
affiliation: Medical Corporation HOUEIKAI, Sekino Clinical Pharmacology Clinic
name: Hisakuni Sekino
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02588378: The Role of Inflammation in AMD and Related Disorders
Official title: In Vivo Visualization of Active Macrophages and Retinal Pigment Epithelium (RPE) Damage in Age Related Macular Degeneration (AMD) & Related Conditions
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Age-Related Macular Degeneration
Lead sponsor: Unity Health Toronto
Sponsor class: OTHER
First posted: 2015-10-27
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Male or female, 18 years of age or older, able to understand the study protocol and provide informed consent.

Brief summary: This prospective, non-therapeutic study will compare the relative utility of multiple ocular imaging modalities in the detection of the cellular immune response in patients with AMD and related disorders.


Eligibility criteria: Inclusion Criteria STUDY EYE

Any tentative clinical diagnosis of the following:

1. Early dry AMD (drusen) with clinical suspicion of CNV
2. Late dry AMD (GA) with clinical suspicion of CNV
3. Reticular Pseudodrusen with clinical suspicion of CNV
4. Polypoidal choroidal vasculopathy
5. Retinal Angiomatous Proliferation
6. Central Serous Retinopathy
7. RPE detachment
8. Conversion to wet AMD (CNV)
9. Decade matched controls

Inclusion Criteria CONTROL EYE

* Subjects \> 18 years of age
* Best corrected visual acuity (BCVA) of 20/32 or better

Exclusion Criteria STUDY/CONTROL EYE:

* Patients not able to provide consent for the study.
* Patients with a poor view of the fundus due to cataract or vitreous hemorrhage.
* Patients \< 18 years of age
* Patients with known allergy to angiographic dye
* Patients with any concurrent unrelated eye diagnosis that would interfere with image acquisition or interpretation (eg advanced diabetic retinopathy, vascular occlusion, uveitis, or others).

Exclusion Criteria CONTROL EYE

* Suspect diagnosis of AMD, RPD, PCV, RAP, CSR or RPED
* Family history of AMD
* 2 or more large drusen (\>125um) or 20 or more medium drusen (64-124um)
* Diabetes
* Patients using Plaquenil/Chloroquine/Hydroxychloroquine
* Diagnosis of inflammatory disease
* Patients with inherited eye disease
* Note: patients with a diagnosis of nevi are NOT excluded from this study

Primary outcomes:
measure: Visualization of RPE damage and presumptive immune cells
timeFrame: 8 months
Secondary outcomes:
Other outcomes:
Locations:
city: Toronto
country: Canada
facility: St Michael's Hospital
state: Ontario
Study officials:
affiliation: Unity Health Toronto
name: Shelley Boyd, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01950078: The Possible Correlations Between the Genes Related to Pain Sensation and the Pain Sensitivity in the General Population
Official title: The Possible Correlations Between the Genes Related to Pain Sensation and the Pain Sensitivity in the General Population
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pain
Surgery
Keywords: gene polymorphism
pain perception
postoperative pain
Lead sponsor: Huazhong University of Science and Technology
Sponsor class: OTHER
First posted: 2013-09-25
Enrollment: 1533
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: anticipative 500 healthy volunteers and 1000 surgical patients

Brief summary: Objective: This study was conducted to explore the possible correlation between some gene related to pain sensation and individual basal pain perception and postoperative pain intensity in the general population. Methods: Patients receiving elective surgery under general anesthesia were recruited into this study. The investigators measured their preoperative pressure pain threshold (PPT) and pressure pain tolerance (PTO). Pain intensity at rest and movement after the operation was evaluated . And the PCA drug consumption were recorded. Also there were healthy college students volunteer be recruited into this study. The investigators measured their experimental pain sensitivity including pressure pain threshold (PPT) and pressure pain tolerance (PTO), etc. Then genotyping was carried out.

Detailed description: Subjects with the following diseases were excluded: known history of chronic disease, psychiatric diseases or communication disorders, diabetes mellitus, severe cardiovascular diseases, kidney or liver diseases with poor hepatic function, alcohol or drug abuse, heavy smoker, Pregnancy or at lactation period .

Eligibility criteria: Inclusion Criteria:

* •Aged 18-65 years

  * Receiving elective gynecological laparoscopic surgery
  * Anesthesiologists (ASA) physical status I or II
  * Agreed to participate the research

Exclusion Criteria:

* •History of chronic pain

  * Psychiatric diseases
  * Diabetes mellitus
  * Severe cardiovascular diseases
  * Kidney or liver diseases
  * Alcohol or drug abuse
  * Heavy smoker
  * Pregnancy or at lactation period
  * Disagree to participate to the research

Primary outcomes:
measure: Preoperative Pressure Pain Threshold (PPT)
timeFrame: 30 minutes before the operation
Secondary outcomes:
measure: Preoperative Pressure Pain Tolerance (PTO)
timeFrame: 30 minutes before the operation
Other outcomes:
Locations:
city: Wuhan
country: China
facility: Department of Anesthesiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
state: Hubei
Study officials:
affiliation: Huazhong University of Science and Technology
name: Zhang Xianwei, MD
role: STUDY_DIRECTOR
References: